Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, GSK Partner on Biomarker Discovery Deal

NEW YORK (GenomeWeb News) – KineMed today announced an agreement with GlaxoSmithKline for the use of KineMed's biomarker discovery platform in therapeutic areas of interest for the drug manufacturer.

The deal is aimed at the discovery, optimization, and validation of novel biomarkers for use in clinical trials directed at compounds for muscle wasting, fibrosis, and metabolic diseases. Marc Hellerstein, KineMed's chief of the scientific advisory board, said that reliable biomarkers that measure the therapeutic impact of drugs on the underlying disease processes are the missing links in developing drugs that target such diseases.

"KineMed's technology, which measures the dynamics of cellular biochemical networks, is focused on developing better metrics of the disease pathology of those disorders and therefore generates competitive advantage in developing effective drugs against them," he said in a statement.

Financial and other terms of the multiyear deal were not disclosed.

Based in Emeryville, Calif., KineMed discovers and develops biomarkers. It announced a deal with CHDI Foundation targeting Huntington's disease, and one with Pfizer to develop diabetes treatments, as GenomeWeb Daily News sister publication ProteoMonitor has reported.